BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
-
AI-generated target was identified through The Benevolent Platform and AstraZeneca s scientific expertise and rich datasets
LONDON, Jan. 27, 2021 /PRNewswire/ BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company s portfolio. The Benevolent Platform predicted this novel target, which was subsequently biologically validated through AstraZeneca s rigorous experimental testing.
In 2019, BenevolentAI and AstraZeneca entered a strategic collaboration aiming to discover new drugs for CKD and idiopathic pulmonary fibrosis (IPF). The partnership combines AstraZeneca s scientific expertise and rich datasets with BenevolentAI s target identification platform and biom
BioArctic receives European patent for new antibodies targeting Alzheimer s disease
STOCKHOLM, Jan. 27, 2021 /PRNewswire/
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aß) and are linked to the company s project AD1503. The patent enters into force on 27 January 2021 and expires in 2030.
BioArctic s newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid beta. Monomers of pE3-Ab are highly prone to aggregate, leading to the formation of harmful soluble Ab aggregates which cause debilitating cognitive and other symptoms in Alzheimer s disease.
Researchers at the Karolinska Institutet in Sweden have shown through their study that Covid-19 patients with severe symptoms have significantly elevated levels of a certain type of immune cell in the